RecruitingNCT06067737
Higher or very low dose psilocybin alongside buprenorphine treatment
About this title
Outpatient Buprenorphine Induction With Psilocybin for Opioid Use Disorder
Read the official source — NCT06067737Medication studyAges 21–70United StatesAddiction
Understand this study
Who could participate?
Listed age limits: 21 years to 70 years.
- Listed locations
- BaltimoreSee all locations and recruitment
- Study phase
- Phase 2Usually explores whether the intervention may work, while continuing to monitor safety.
What to know before participating
A point to clarify
This summary does not cover all risks or eligibility requirements. What risks or changes to my care would apply to me?
Things to check before joining
Study start dateStarted: February 8, 2024
- Recruitment status
- Recruiting
- Enrollment listed in the registry
- 90
- Sponsor
- Johns Hopkins University
- Sponsor type
- University
- Study type
- Drug
- Intervention type
- Drug
- Study phase
- Phase 2Usually explores whether the intervention may work, while continuing to monitor safety.
- Locations
- United States
- Age range
- From 21 Years to 70 Years
- Official registry ID
- NCT06067737
- Official title
Show the full official title
Outpatient Buprenorphine Induction With Psilocybin for Opioid Use Disorder: a Randomized Double-blind Trial
Recruitment & locations
Currently recruitingA study may be recruiting, but some locations may no longer be accepting participants. Confirm availability with the research team.
Baltimore
Interested in joining this study?
Questions about this study
Who is behind this study?
The study sponsor is Johns Hopkins University, a university.
Does this study involve medication?
Yes. The study involves medication, including Psilocybin.
Who can participate?
Listed age limits: 21 years to 70 years.
Is this study still recruiting?
The registry lists this study as recruiting.
